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The Ethical Component of Organ Donation 
History of Giving the Gift of Life 
 The dream of curing illness and injury by transplanting organs, bone, and other tissues 
dates back to the Middle Ages. Unfortunately the scientific knowledge and surgical techniques 
that have made modern transplant medicine possible had to wait until the nineteenth and 
twentieth centuries to make their debut. Successful transplantation of bone, skin and corneas 
came early but was far from sophisticated. The first “miracle” transplantation of a kidney was 
performed between two monozygotic twins in 1954 by Dr. Joseph Murray and Dr. John Merrill 
of Peter Bent Brigham Hospital, and the question was quickly raised how to transplant organs 
between patients who are not identical (Jonsen, 2012). Although many obstacles remained at this 
point, the era of transplantation was on the horizon and people everywhere recognized it as an 
extraordinary leap in medicine. Important medical breakthroughs two decades or so later - such 
as tissue typing and immunosuppressant drugs - allowed for the successful transplant of larger 
organs between two people who were not related. Dr. Christian Barnard, in 1967, transplanted a 
still-beating heart into a patient who lived for eighteen days; less than a month later he attempted 
again and this time the patient lived for 594 days (Jonsen, 2012). By 1968 the first organ 
procurement organization was established along with the Uniform Donor Card as a legal 
document in all fifty states. What was once deemed impossible was now becoming a reality, but 
of course the roadblocks did not stop there. No longer is the problem how to perform organ 
transplantation surgeries or how to keep bodies from rejecting them, but the lack of supply due to 
a lack of registered donors. Ethical dilemmas were noticed lurking in the miracle, specifically 
with regard to physicians risking the health of a well person to save a sick one.  
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 Physicians sign the Hippocratic Oath, promising to do no harm. One of the first 
predicaments of this breakthrough in medicine was that no matter how pure the motives, living 
organ donation attempts to make a sick person well by wagering the physical condition of a 
healthy person. People soon began to realize that this was not the only piercing question that 
needed to be addressed. How could consent be obtained without coercion (Jonsen, 2012)?
Regarding deceased donors, what clinical evidence of death does there need to be? If the donor is 
not related to the one needing a transplant, should there be compensation? As transplants become 
more consummate, how should the recipients of these organs be fairly selected? How will there 
ever be enough organs or organ donors to meet the need? These were just the start of questions to 
be tackled and now they form the framework on the policy of organ transplantation.  
 There are many leading countries that have presumed consent laws for transplantation as 
opposed to the expressed consent laws that the United States currently has in place. Presumed 
consent is alternatively known as an ‘opt-out’ system and means that unless the deceased has 
expressed a wish in life not to be an organ donor, then consent will be assumed. Almost all that 
have adopted a presumed consent law as opposed to an expressed consent law have seen a very 
significant increase in organs for transplantation (Zink, 2005). The United States has not 
followed the way of the majority because they believe there is a loss of patient autonomy, and a 
potential violation of the 5th amendment. Although a presumed consent policy gets around the 
issue of coercion, it is understandable why the U.S. does not have that approach in place. For 
those countries that do, there is a legislative framework in which citizens must place their name 
on a national withdrawal registry, otherwise their organs will be removed for donation after they 
are pronounced deceased (Fabre, 2014). 
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 In the 1960s, discussion arose on what clinical evidence is sufficient to determine 
whether or not a person is dead. It was proposed by Henry Beecher that a person could be 
diagnosed as dead when there was “irreversible cessation of the function of the entire 
brain” (Sade, 2011, p. 146). This status has since become known as brain death and has been 
codified in the law of every state by their adoption of the Uniform Determination of Death Act 
(UDDA). People now recognize that there is only one kind of death, but that it can be determined 
by the two different ways described in the law. A brain dead individual with a still-beating heart 
is just as dead, legally, as someone whose body has become stiff because their heart permanently 
stopped beating. The current system has been in effect for decades now, but there is still 
controversy over brain death checking the box for the dead donor rule, which requires a person 
to be declared dead before the removal of their organs for transplantation. Removing of organs 
would most definitely stop someone’s heart from beating, whereas being brain dead would not. 
However, the UDDA assures patients, families, and health-care professionals that a patient who 
is brain dead is in fact dead, making the removal of organs for life-saving transplantation “legally 
and ethically acceptable” (Sade, 2011, p. 147). One thing that the law does not concede or accord 
is that the families of these deceased donors — or living donors — will receive any type of 
compensation for their organs. 
 One of the most easily answered questions that was posed at the start of organ 
transplantation involved compensation — mainly financial — for donors, primarily those who 
were living. Leading transplanters and scholars in the law at that time decided that organs must 
always be donated and explicitly granted by the donor (Jonsen, 2012). A spirit of altruism and 
volunteerism are necessary to use a natural resource for the common good.  This was ultimately 
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an ethical decision that would prevent commercialization of organs, exploitation of the healthy 
poor, and promote equality in organ distribution. However, there is now a continually widening 
gap between the number of patients needing an organ donation and the number of those 
available. For those who have not been waiting near as long or who are not in as dire of a 
medical need, the gap is significantly wider.  
 Organs are limited resources in a majority of countries, and the justice-based system in 
place right now prioritizes patients based on their medical status and urgency of their need 
(Cameron, 2008). Under the National Organ Transplant Act, organ transplantation in the United 
States is overseen by the U.S. Department of Health and Human Services. Organs are allocated 
— blind to name, race, sex, and wealth — according to strict rules that take into account physical 
matching, tissue and blood type matching, medical criteria, waiting time, and severity of illness. 
The allocation system’s rules have been developed over many years by physicians and 
transplantation experts and continue to update as there are new changes in the field of medicine. 
One of the largest issues facing the department right now is that the success of organ transplants 
in treating end-stage organ failure has generated an unprecedented demand for transplantable 
organs that unfortunately remain in short supply.  More than 116,000 patients were on the United 
States transplant waiting list, but only 28,000 transplants were performed (Razdan et al., 2015). 
Those statistics reveal that less than twenty-five percent of people needing an organ donation 
received one, and sadly there has not been a significant increase in that number over the last 
eight years. The gap is so wide that there has been discussion of not allowing prisoners to be 
placed on the organ transplant waiting list. Increasing the availability of transplantable organs 
and willing donors is therefore critical in preventing deaths from organ failure. 
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 There is a continually widening gap between the number of patients needing an organ 
donation and the number of those available. This growing shortage will continue to persist — 
and there will never be enough organs to meet the need — unless something is changed. The 
ability of physicians to treat patients facing organ failure is largely dependent on public 
willingness to supply them (Laden, 2016). Although there is a strong support for organ donation 
across the United States, there is still a lack of organs for treatment of organ failure. There are a 
lot of concerns that need to be addressed to increase the supply of organs, and all of the questions 
addressed above are just the beginning. Many people believe that physicians have an obligation 
in facilitating education and discussion with their patients regarding organ donation (Ladin, 
2016). Although, health authorities should be morally compelled to intervene and make sure that 
the public is aware of how they can have an impact on organ donation, the weight should not 
only be on their shoulders. The reality is that there are simply not enough organ donors to meet 
the demand, but there are several explanations for this ongoing shortage.  
Present Policies are Falling Short 
 Despite the slight increase in the rate of organ donations from deceased donors, the 
demand still exceeds the supply of transplantable organs. And public policies have done little to 
close this gap. Changing policies to account for the lack of post-medical care costs and lost 
wages given to living organ donors by organ recipients is a start. A change in the current 
philosophy of social education policies regarding organ donation and transplants is clearly 
necessary, as recognition and support by health and education organizations would undoubtedly 
make people aware of this issue. A “no-give, no-take” policy could be enforced that requires 
people to be an organ donor before they can receive one from someone else. In addition, 
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formulating a public policy that promotes organ donation through state incentives. Present 
policies seem to be falling short when it comes to increasing the number of available organ 
donors, but the proposed alterations and additions above could make a difference. 
 In the United States and other countries, live organ donation tends to be costly and 
burdensome for those people who are willing to give their organs. While the majority of medical 
costs are covered, many donors still face lost wages, travel expenses, and medical expenses that 
may come from complications after organ removal. Despite the widespread agreement that living 
donors should not be left with any financial burden from their donation, not a lot has been 
accomplished to alleviate those costs. The failure of policies to eliminate these out-of-pocket 
costs for living donors may be a contributing factor to the lack of willing patrons. A goal of 
financial neutrality for the living donor should be sought and upheld; coverage/reimbursement of 
all medical, travel, and lodging costs in addition to lost wages and any other expenses related to 
the organ donation (Hays et al., 2016). Risks of job loss and insurability after donation can only 
be addressed and taken care of with policy and legislative improvements. Although the notion of 
financial neutrality for living donors is not controversial, nothing has changed. Achieving total 
compensation for those willing to give their organs should be considered a policy priority if there 
is to be a decrease between the gap of needed and available organs. Until such policies are 
developed, transplant hospitals should ensure that contracts with those paying for the organ 
relocation include adequate coverage for the living donor.  
 The widening gap between needed and available organs for transplantation is not going to  
decrease if the public is not aware of this issue. Ignorance is one of the leading causes of 
society’s lack of response to the demand for organ donation, especially in regard to deceased 
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donation (Ladin, 2016). The media is a large contributor to this ignorance with false reports on 
organs going to the rich first and then to the poor, the lack of properly trained medical officials, 
fears concerning a misdiagnosis of brain death, and even stories about criminal organ commerce. 
With proper education and information on all of the logistics regarding organ donation, people 
would understand that posts by media outlets — such as those listed above — are not to be taken 
seriously. Polices that require public education, mainly through proper media coverage, non-
governmental organizations and lectures by experts, should be implemented as a strategy to 
change social attitudes toward organ donation.  A social education policy that promotes the 
incorporation of topics on donation and transplants in curricular programs, periodically carried 
out in schools, colleges and universities, would certify that people understand the seriousness of 
the need for registered organ donors. Furthermore, implementing information to modify the 
current reluctant negative behavior toward organ donation by society constitutes a potential 
possibility to improve this urgent medical-social crisis. Policies that focus on the education and 
awareness of the public regarding organ donation would potentially increase the number of 
registered donors.  
 The death of thousands of Americans on the organ transplant waiting list could be 
prevented if more people were registered donors; therefore, changes to the present policies or 
addition of new policies regarding donation is necessary. To solve this organ shortage, many 
nations have considered implementing a “no-give, no-take” allocation policy that would prevent 
people who are not registered donors from receiving an organ transplant. Under the current 
system, non-donors have just as much access to the organ pool as donors because the United 
Network for Organ Sharing regards organs as being a natural resource. However, it is not morally 
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just for a non-donor to receive this resource before a registered donor. Giving priority for organ 
transplants to those who have already agreed to donate creates an incentive to sign an organ 
donor card and imposes a penalty for those who do not sign, thereby increasing the number of 
transplantable organs. There are several advantages to this “no-give, no-take” policy — one 
being that is satisfies peoples moral intuitions. Many find the idea of paying for organs as 
distasteful but are comfortable with the morality of reciprocity; it does not deem human beings 
as a commodity. Adopting policies like “no-give, no-take” increase the public incentive to 
donate, which in turn increases the total number of organs available for transplantation. 
 The miracle of organ transplantation saves the lives of thousands every year, however, the 
chronic organ shortage that leads to substantially more deaths overshadows this success. This 
dilemma is a public health problem due to its grave consequences on transplant patients and 
society as a whole. Promotion of a public policy through various state incentives that express 
gratitude for the solidarity act of the donor could potentially curve this issue. It would provide 
the necessary stimulus to overcome individual’s negligence and apathy, specifically the majority 
who are inclined to donate but have not taken action yet to be a donor. Some of these incentives 
might include — but are not limited to — tax credits, discounts on health insurance premiums, 
and contributions to funeral costs for deceased donors (Levy, 2018). There is a public interest in 
improving organ donation rates to decrease the cost burden on health care systems and social 
security systems, and also to fight against organ trafficking. Consequently, the state assumes 
multiple roles in transplantation medicine, one of them being to encourage donation and increase 
the number of available organs. Public policies through various state incentives would 
accomplish that task; however, the common contention that incentives are not ethical presents a 
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road block. The question now becomes not whether the state should encourage individuals’ 
willingness to donate but how. 
Getting more Organs — Are Incentives Ethical? 
   It cannot be denied that the shortage of organs available for transplant is a serious 
problem worldwide. Incentives for organ donation are currently prohibited in most countries, but 
the truth is that they may increase donation and save lives. Discussions of increasing the number 
of available organs with the help of incentives has been focused on two reservations: whether or 
not there are ethical principles that justify the current prohibition and whether incentives would 
do more good than harm. Legally, the sale or purchase of human organs is not allowed. 
Currently, the only form of compensation that is permissible is the reimbursement of expenses 
acquired by the donors and related to their donation. The purpose of these payments is to 
alleviate financial loss living donors might experience as a result of their much-appreciated 
donation, as opposed to the financial incentive used to encourage a person to donate. Essentially 
the difference is when this compensation is given and how it is used; to a willing-donor after 
their donation to cover medical costs or to a financially unstable person before their donation to 
pay monthly bills. A lot of this discussion is focused towards living donors but can also be 
applied to deceased donors who may seek coverage of their funeral costs. The ethical landscape 
regarding incentives for organ donation is convoluted with some people proposing that any form 
of inducement is not permissible, while there are others who think that any un-harmful way of 
encouraging organ donation is necessary. 
 Incentives are defined as being a stimulant that encourages or motivates a person to do 
something. In terms of organ donation, these incentives can either be financial by having 
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material gain or value or non-financial by having no material gain or value. The field of organ 
donation focuses heavily on making sure that their standards and policies are ethically 
upstanding, as to promote the welfare of society. Regarding incentives—both financial and non-
financial—there are a lot of people who hold to the opinion that neither is ethically objectionable 
in terms of organ donation; whatever lawfully increases the number of available organs is 
equitable. Ultimately, people promoting these for donors conclude that their motives are ethical 
because they are solely based on the concern for the well-being of patients and saving the lives 
of those who desperately need a transplantation. In turn, incentives would also decrease or 
eliminate unregulated and illegal organ trade markets. Trafficking in human beings for the 
purpose of organ removal and organ trade is universally condemned, yet it is presumed that 
almost 10,000 transplants occur annually in this way (Caulfield, 2016). A carefully regulated and 
principled system of incentives for donation could not only diminish organ commerce, but it 
could also potentially provide extensive benefits to both recipients and donors. Therefore, it is 
worthy of systematic investigation. Furthermore, surveys have shown that the public not only 
supports incentives but would be more likely to donate if they were offered incentives. 
(Incentives for Organ Donation: Proposed Standards for an Internationally Acceptable System, 
2011). Arguments in favor of incentives or organ donation are founded in hope that this system 
would increase the supply of organs and thereby validate the ethical concern of saving lives that 
may otherwise be lost due to lack of this resource. Despite these seemingly accurate points, 
compelling arguments against financial and non-financial incentives for organ donation have 
been persuasively made as well. 
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 Living and deceased organ donation poses a fundamental ethical challenge: should 
incentives be used to increase transplantation numbers or by using them are people being viewed 
as a commodity. Selling organs, mostly kidneys, is banned by law in practically every Western 
country (Sells, 2004). This is not the case for Iran where payment for kidneys has been legalized 
and capitalized by their government. Although they are one of the very few countries with no 
waiting list for kidney transplants, the United States and others cannot ethically wrap their heads 
around this type of incentive. Many opponents point out that there would not only be a loss of 
emotional gain and personal linkage, but also a decreased respect for life and sanctity of the 
human body. The argument is that incentives and paid donation do not embrace the Hippocratic 
Oath or protect the interests of the donor. This shift in balance of responsibility to the paying 
recipient may increase the number of organs available for transplant, but many view this as 
disturbing and unethical. If payment for donation was legalized, those with a greater financial 
need would be more likely to donate, and there does not need to be a potential rich versus poor 
contingency. To understand this fully let us look at the demographic of the donors that would 
result from this type of situation. Donors are lacking financial stability, most of them below the 
poverty line. Most are uneducated and in low-paid manual jobs — not seeking to donate out of 
altruism or a feeling of moral obligation but to pay their bills. In fact, most living donors who do 
sell their kidneys fall back into debt due to a decline in general health from losing that organ.  
Most people, although eager to increase the number of transplants, would argue that the buying 
and selling of human organs can never be made ethical because it will always somehow penalize 
the weakest in society or exploit the poor. Financial gain should never take precedence over 
patient care, and that is why the current system promotes altruistic donation. 
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Altruism and Moral Obligations 
 Altruism can be defined as the belief in or practice of selfless concern for the well-being 
of other people. Living and deceased organ donation are formulated around this idea of giving 
without seeking reciprocation. Altruism has been an integral part of transplantation from the 
beginning: the gift of life and science to humanity; grieving family members who offer to donate 
the organ of a deceased loved one; and recipients who consent to participate in life-saving 
scientific research. In fact, many organ procurement organizations and medical associations such 
as American Society of Transplantation (AST) and United Network for Organ Sharing (UNOS) 
clearly assert that organ donation and transplantation should maintain voluntariness of choice 
and an altruistic foundation (Fortin et al., 2010). It is believed that a donation is only considered 
altruistically motivated if the organs are available for allocation to recipients with whom the 
donor does not have a personal connection, or if they are receiving no direct-benefit. However, it 
is almost impossible to determine what a donor’s motives are. Therefore, many believe that 
altruism should be desired in donation, but in order to increase transplantation numbers, it should 
not be a requirement. Altruism has been the guiding principle of ethical organ donation and has 
been used as a justification for rejecting or allowing certain types of donation (Moorlock  
et al., 2014). 
 Organ donation and transplantation is deemed by many to be the gift of life and science 
to humanity; it is not just a complex medical process but a personal human deed. This form of 
altruism touches people closely and intimately, and through which the recipient gains a lease on 
life, an enhanced quality of living, and a newfound respect for humanity. Many people believe 
that if there was no longer a moral obligation or conscious desire to give out of selfless concern, 
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then there would be a lack of this personal connection; it would no longer be deemed a gift of 
life. Donor families and recipient families each have their own story to tell. Each story is as 
different as each individual. One aspect that they have in common, however, is the uncommon 
generosity of the human spirit during a time of great need and tragedy. Organ donation gives 
people the chance to rise above personal concern or gain by helping others in need of a life-
saving transplantation. This opportunity is life-giving and life-changing to those who are at the 
end of the line for hope.  It also affects the families, friends, colleagues, and acquaintances who 
love and support those in need of transplantation and who benefit from their renewed life and 
improved health after transplant. Organ donation is only termed the gift of life because of the 
role that altruism plays in its foundation; that term can be seen at its peak when grieving family 
members offer to donate the organs of a deceased loved one.  
 Good deeds and actions can result from tragedies, and organ donation is just one 
example. A family grieving over the loss of their child to an automobile accident can receive 
comfort in knowing that they are giving another human being a second chance at life when they 
are willing to make a donation. In some cases, more lives than one can benefit from the gift; a 
mother of five children receiving a heart; a widow with grandchildren receiving a new set of 
lungs; a teenager on dialysis receiving a kidney. Donor families embrace this sense of altruism 
when donating their loved one’s organs and can in-turn take comfort in the idea that their loved 
one’s legacy was one of life and giving. It is widely thought that there are benefits in the practice 
of altruistic donation. For donor families, specifically, they garner a feeling of consolation in 
knowing that their love one’s death could ultimately be used for good. To multiply that altruism 
and have other good come from a tragic loss, that organ recipient could volunteer to participate 
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in life-saving research that may help in future transplantations. There are many aspects of a 
transplantation that — if done altruistically — can result in a rewarding and enriching outcome 
for both the donor, their family, and the recipient.   
 Altruism is desired for all aspects of organ donation; those situations involving donor 
families and even instances where transplant recipients desire to be included in a research study 
after their operation. The organ donation and transplantation system strives to honor the gift of 
donated organs by fully using those organs to save or improve the quality of the lives of 
transplant recipients. As a result of advances achieved through basic and clinical research over 
the past several decades, organ transplantation has become the optimal treatment for many end-
stage organ-specific diseases. Furthermore, there are many aspects of organ transplantation that 
need to be improved upon, and one of the best ways to do that is by conducting research 
involving organ recipients. To date, organ transplantation research has focused almost 
exclusively on transplant recipients and on finding ways to improve transplantation processes 
and post-transplant health outcomes. With the help of altruistic transplant recipients, new 
methods can be identified that improve the quality and increase the quantity of organs for a 
successful transplantation. These people have been given a second chance at life, and research 
studies focused on improving organ transplantation could be their way of thanking that living or 
deceased donor for giving them the opportunity to lead a fulfilled and healthy life. 
Deceased Donors and Cold Storage Solution 
Living versus Deceased Donors 
 When it comes to the organ transplantation process, there are two ways that organs can be 
retrieved: from a living donor or from a deceased donor. The network has policies that regulate 
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how these donor organs are matched to patients on the waiting list, such as blood type, body size, 
and distance between the donor’s hospital and the patient’s hospital. The obvious difference 
between a living and a deceased donor is that one person is living and the other person is not. 
However, there is also a difference between what organs they are able to donate, the way those 
organs are prepared and transported, and even the overall outcome of the recipients. Living 
donors are few and far between when compared to the number of deceased donors, because they 
are essentially having to risk their own life and health to save that of another person. In 2018, 
however, the number of living donor transplants was the highest it had been since 2005, claiming 
almost 18% of more than 36,500 total transplants (2018 Living Donor Transplants Increase 11 
Percent, 2019). The majority of the time, these donors are giving their organs or a part of their 
organs to either a family member or someone they know. For a lot of people in this case, the 
benefits of having their loved one for longer outweigh the risks of any short-term or long-term 
damage. Living donations, although offering more advantages for the recipient of an organ 
transplant, are harder to come by because they are limited on what organs they are able to give 
and they risk the health and life of not only one but two people.  
 When it comes to available organs for transplantation, it is obvious that deceased donors 
have less limitation than living donors on what they are able to give. Living donors are limited to 
giving one kidney, a lung, or a portion of the liver, pancreas or intestine. Deceased donors are 
able to give two kidneys, two lungs, liver, heart, pancreas, eyes, or various tissues. For both 
types of donation, the kidney is the most commonly transplanted organ. In 2019, renal 
transplantation accounted for 60% of the total transplants performed that year (Organ Donation 
Statistics, 2020). This large number is attributed to end-stage kidney disease which can be caused 
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by diabetes, high blood pressure, and anatomical problems of the urinary tract. Most people can 
undergo treatment with dialysis, but transplantation offers the closest representation of a normal 
life because the transplanted kidney can replace the failed kidney. This is the case for all other 
types of organ failure as well; transplantation is the ideal option. Furthermore, if living donation 
is available, it is preferred over deceased donation because they normally result in far better 
outcomes for the organ recipient.  
 Although deceased organ donation is much more common than living organ donation, the 
latter offers several advantages for the recipient of an organ transplant. Transplantation surgeries 
involving organs from a living donor can be scheduled in advance, ensuring that the transplant 
occurs at an optimal time. Many people with organ failure are still able to maintain a job if their 
health allows, so being able to schedule time off of work is an advantage. Also, living organ 
donations tend to become available before the recipient has to be placed on the waiting list or 
before they begin treatments, such as dialysis that accompanies renal failure. This not only 
prevents the patient’s health from deteriorating further, but it also saves them from any stress that 
comes from anticipation. Finally, living donor organs tend to have greater longevity than those 
transplanted from a deceased donor; they may become stressed by having to spend a longer time 
in a cold storage solution while they are being transferred between hospitals. The use of these 
preserving compounds can temporarily reduce organ function, resulting in an organ that is not 
fully functional until days or weeks after the transplant. 
Cold Storage Solution and Transplantation 
 Organ transplantation is the most effective therapy for patients with end-stage organ 
disease. Preservation solution and techniques are crucial for keeping the organ viable during 
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transportation, which is directly related to morbidity and survival rate of the patient after 
transplantation. By the start of clinical transplantation, there was already a significant amount of 
knowledge acquired by physiologists and anatomists on how to keep organs functioning outside 
of the body. Since the 1960s, static cold storage (SCS) has been the preferred method for 
sustaining these organs from the time they are taken out of the deceased donor and placed into 
the recipient. It is deemed as the “supply line” for organ transplantation by allowing time for 
surgery preparation, allocation and transit of the organ, and running of laboratory test to ensure 
fitness of the body part for a specific patient. However, prolonged time in this solution has been 
shown to increase the risk of damage to the organ that can result in more complications down the 
road (Jing et al, 2018, p. 845). Also, there have been difficulties with assessing donor organ 
function and viability after preservation in cold storage.  
 Many early, pivotal discoveries in medicine have allowed for the organ preservation 
system that we see today. Starting with the first closed artificial circulation system that was 
constructed by Max von Frey and Max Gruber (Jing et al, 2018, p. 846) This discovery allowed 
for organ perfusion to continue for several hours without having to be interrupted to resupply 
oxygen to the blood that was flowing out of the tissues. Historically, blood was used as a 
perfusate in early apparatuses, but because this required a large supply of blood to operate, 
scientists began to experiment with altered or new perfusates. They attempted to use a different 
animal’s blood but the use of cross species was toxic to the graft. Scientists then diluted the 
animal’s own blood using saline but this led to severe edema in the lungs. These discoveries led 
to the transition of using blood as a perfusate to a more successful, chemically defined perfusion 
solution. Along with these findings, scientists also realized that colder temperatures, as opposed 
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to room temperature perfusion, might lessen organ damage by mitigating cellular metabolism. 
Considerably lowering the temperatures of the solution, in fact, extended organ preservation 
from hours to days. All of these experiments and findings lead to a simple method for organ 
preservation that was more cost-efficient and favorable for organ transportation than its 
predecessors. The birth of SCS replaced dynamic perfusion methods and became the standard 
method of organ preservation that hospitals still use to this day.  
 Since the 1960s, SCS has gradually become the preferred method of organ preservation 
for transplantation surgeries. With the shortage of organs available for transplant, it is crucial that 
the organs that are donated are functioning at their highest possible capacity, and organ 
preservation is a crucial step in producing that outcome. The main goal in organ preservation is 
to maintain function of the organ and tissue during storage so that the graft will function at re-
perfusion, when the blood flow is restored. The process of SCS involves flushing the procured 
organ with preservation solution at 0–4 °C, then immersing it into preservation solution at the 
same temperature until transplantation (Jing et al, 2018, p. 846). The hypothermic environment is 
responsible for abating the rate of cellular metabolism, and the preservation solution provides 
protection for the tissue against harmful agents. These cold storage solutions also contain 
antioxidants and nutrients that sustain the cells and slow inflammation, but doctors are beginning 
to realize that is not always enough. In 2016, there were a total of almost 5000 recovered organs 
that were not transplanted, and a large percentage of that number was due to prolonged cold 
storage of those organs in the preservation solution (Kindy et al, 2018). The majority of organs 
can only tolerate 24 to 48 hours of cold ischemia before they are no longer functional, but every 
hour spent in storage solution results in more damage to the tissue. This prolonged state of 
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hypothermia is supposed to limit ischemia-reperfusion injury, but it actually results in cellular 
edema and eventually cell death. With the already limited amount of deceased donor organs 
available, it is absolutely crucial that all available organs are used for transplantation. Although 
the use of SCS has been proven to cause damage to the tissue, it is still essential for preservation 
of the organs during transplantation. Many research groups have focused on targeting the 
methods of destruction of this cold storage solution so that they can protect organs from further 
tissue damage, and also allot more time — when needed — for transplantation. In fact, a 
research lab at Arkansas Children’s Research Institute in Little Rock, Arkansas is doing just that.  
The Parajuli Lab 
 Identifying pathways related to renal cold storage that lead to renal damage after 
transplantation will help design novel pathway-specific therapies to improve graft outcome. The 
focus of the Parajuli Lab at Arkansas Children’s Research Institute is centered around that goal 
of improving transplant outcomes by identifying cold storage-mediated renal damage and by 
acquiring targeted therapies during cold storage. Leading this research team is Dr. Nirmala 
Parajuli who also serves as assistant professor of Pharmacology and Toxicology at the University 
of Arkansas for Medical Sciences. Using male Lewis rats as transplant donors and recipients, her 
team has been successful in emulating transplant conditions for further research. So far, their lab 
has shown that mitochondrial function of the kidneys was compromised after cold storage alone, 
and this was exacerbated when cold storage was combined with transplantation. A recent report 
showed in a rat model of renal transplantation that mitochondrial dysfunction precedes 
compromised proteasome function and this results in a vicious cycle of mitochondrial injury and 
proteasome dysfunction. Also, they have come to realize that there are therapeutics, such as 
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Mitoquinone, that preserve mitochondrial and proteasome function during cold storage that may 
provide beneficial outcomes following transplantation. In addition, the researchers at the Parajuli 
Lab have found that proteasome inhibition/down-regulation increases reactive oxygen species, 
which then impairs proteasome subunits in renal proximal tubular cells. All in all, they have 
established that oxidant production increases during cold renal preservation, and mitochondria 
are a key target for injury. Cold preservation has greatly facilitated the use of cadaveric kidneys 
for transplantation but damage occurs during the preservation episode. In the summer of 2019, I 
was given the great opportunity to serve as a research intern in the Parajuli Lab, researching the 
effects of renal cold storage and transplantation on immunoproteasome and the complement 
system.  
Introduction to Research 
Renal transplantation is the preferred method of treatment for end stage kidney disease. 
The majority of donor kidneys come from deceased donors and have to be stored in cold storage 
solution (CS) until the recipient is identified. However, prolonged CS is associated with poor 
long-term outcome. Unfortunately, the mechanisms of CS-related damage are largely unknown. 
Our laboratory recently reported that the proteasome and renal function were significantly 
decreased in rat kidney transplants that involved CS combined with transplantation (CS/Tx), as 
opposed to those that did not undergo CS (auto-transplantation/ATx). The long-term goal is to 
improve the transplant outcome by identifying CS-mediated renal damage and by acquiring 
targeted therapies during CS. This study contributes to that objective by characterizing 
immunoproteasome (a proteasome variant) and the complement system (a group of serum 
proteins that participates in eliminating pathogens and debris) activation within the kidneys after 
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CS/Tx. Our hypothesis is that CS/Tx will exacerbate the function of immunoproteasome and 
complement systems. Lewis rat kidneys exposed to 18 hours of cold storage were used for 
transplantation (CS/Tx). Kidneys with no CS exposure were transplanted (ATx) and used as a 
transplant control. The sham (Sh) kidneys with right nephrectomy were used as a control. Using 
paraffin embedded kidney sections and immunohistochemistry/immunofluorescence, 
immunoproteasome and complement levels/function were evaluated. Immunoproteasome 
function was significantly increased only after CS/Tx when compared to Sh and ATx. 
Immunohistochemistry of kidney sections revealed a modest increase of immunoproteasome 
catalytic subunits, LMP2 and LMP10, after ATx when compared to Sh, but a profound increase 
of these subunits was detected after CS/Tx. Similarly, complement proteins C3 (an upstream 
component) and C5b-9 (a cytolytic terminal activation product) were increased in kidneys after 
ATx (detected by immunofluorescence), but an excessive increase of these proteins was observed 
after CS/Tx. Furthermore, TUNEL assay revealed exacerbated cell death in kidney sections after 
CS/Tx, whereas ATx showed a slight increase of cell death. These results suggest that the 
prolonged CS worsens activation of the immunoproteasome and complement system, further 
leading to renal damage and dysfunction. 
Background
My research was focused on researching the effects that renal cold storage and 
transplantation had on immunoproteasome, which is a variant of the constitutive proteasome (as 
shown by Figure 1), and the complement system, specifically the pathways C3 and C5b-9. The 
constitutive proteasome is a protein degradation missionary that maintains homeostasis in the 
cell. It has already been shown by the Parajuli Lab that proteasome function is compromised in 
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CS/Tx. In Figure 1, the bar graph shows that the constitutive proteasome saw more dysfunction 
and less activation in the CS/Tx kidney as opposed to the Sh kidney. During stress, inflammatory 
cytokines are released, triggering activation of the immunoproteasome. Using a western blot, the 
lab had already started researching the effects of CS/Tx on the B2i (LMP10) and B5i (LMP7) 
components within the immunoproteasome beta ring. Their results in the graph in Figure 1 show 
that there was a higher amount of immunoproteasome activation in the CS/TX kidney as opposed 
to the Sh kidney. This means that there was a higher number of inflammatory cytokines released 
due to stress. I was given the task of researching the effects of CS/TX on B1i (LMP2) and B2i 
(LMP10) within the immunoproteasome beta ring. 
My research was also focused on studying the effects that renal cold storage and 
transplantation had on the complement system, specifically the pathways C3 and C5b-9.  
22
Figure 1. Immunoproteasome
The complement system is a group of serum proteins that detects and gets rid of pathogens 
within the tissue. It specifically functions as a part of the immune system that enhances the 
ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, 
promote inflammation, and attack the pathogen's cell membrane. There are three biochemical 
pathways that activate the complement system (alternative, lectin, and classical) as shown in 
Figure 2. The focus of my research, however, was not on those three pathways specifically, but 
what they all merge on: C3, an immune system protein. When stimulated by one of several 
triggers, C3 is activated and a cascade begins that further triggers C5b-9. This final point in the 
complement cascade serves as a cytolytic membrane attack complex that if deposited in the cell 
leads to cell lysis or cell death, as shown in Figure 2. The end result is stimulation of phagocytes 
to clear foreign and damaged material. 
Materials and Methods 
All protocols in this section were replicated from research conducted by Dr. Nirmala Parajuli 
(Parajuli et al, 2011; Parajuli et al, 2017).  
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Figure 2. Complement system
Animals: Male Lewis rats (200 –250 g) were used as transplant donors and recipients. All animal 
protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Arkansas for Medical Sciences (UAMS), and all animal experiments were 
performed in compliance with institutional and National Institutes of Health guidelines. 
Orthotropic Renal Transplant Surgery: For donor surgeries, rats were anesthetized with 
isoflurane, and the left and right kidneys were removed and flushed with and stored in UW 
solution at 4°C for 18 h. The right kidneys of donor rats were referred to as the CS group (as 
shown in Figure 3). For recipient surgeries, rats were anesthetized with isoflurane, the native left 
kidney was removed, and the donor left kidney (exposed to CS) was transplanted. The native 
right kidney was immediately removed so that renal function was entirely dependent on the 
transplanted left kidney.  After 24 h of reperfusion, the transplanted left kidney and blood were 
collected under anesthesia and saved as the 18-h CS/Tx group (as shown in Figure 3). 
Autotransplant surgery: Autotransplant (ATx) surgery was included in these studies so that the 
impact of CS could be isolated from the impact of transplant surgery alone. ATx was performed 
(as shown in Figure 3); the left kidney was removed, flushed with saline, and immediately 
transplanted back into the same rat without CS exposure. After 24 hours, the transplanted kidney 
was harvested under anesthesia; these kidneys were referred to as the ATx group.  
Sham surgery: Rats underwent the same procedure for right nephrectomy but without renal 
transplantation (sham operation in Figure 3); the right kidney was saved as a control kidney.  
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The left kidney and blood were harvested 24 h later and saved as the sham group. 
  
Immunohistochemistry: For immunohistochemical analysis, antigens were retrieved by heating 
sections in 10 mM sodium citrate buffer (pH 6.0) for 20 min. Endogenous peroxidase was 
quenched by incubating the sections with Peroxidase Suppressor (Thermo Scientific, Rockford, 
IL, USA) for 15 min at RT. The slides were blocked with Non Serum Protein Block (Dako, 
Carpinteria, CA, USA) for 20 min at RT. Primary antibodies were prepared in antibody diluent 
solution (0.5% non fat dry milk and 1% BSA in TBS) and incubated for 1 hour at room 
temperature. Counterstaining was performed with Mayer's Hematoxylin (Electron Microscopy 
Science). All images were taken using a Nikon Eclipse E800 microscope (Q Capture imaging 
and Nikons Elements software) Semi-quantitative evaluation of nitrotyrosine staining was 
performed based on the percentage of positive tubules in 10 high power fields (200×) from 
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Figure 3: Rat Renal Transplantation Model
cortex and medulla using the following scores:  0 - null/negative; 1 - 10% positivity; 2 - 25% 
positivity; 3 - 50% positivity; 4 - 75% positivity; 5 - 100% positivity.  
Immunofluorescence: For immunofluorescent analysis, antigens were retrieved by heating 
sections in 10 mM sodium citrate buffer (pH 6.0) for 20 min. Endogenous peroxidase was 
quenched by incubating the sections with Peroxidase Suppressor (Thermo Scientific, Rockford, 
IL, USA) for 15 min at RT. The slides were blocked with Non Serum Protein Block (Dako, 
Carpinteria, CA, USA) for 20 min at RT. Primary fluorescent antibodies were prepared in 
antibody diluent solution (0.5% non-fat dry milk and 1% BSA in TBS) in the dark and incubated 
overnight at 4°C. Counterstaining was performed with DAPI (4′,6-diamidino-2-phenylindole). 
All images were taken using a Nikon Eclipse E800 microscope (Q Capture imaging and Nikons  
elements software). Semi-quantitative evaluation of the cortex and medulla staining was 
performed based on fluorescent levels detected by the ImageJ software.  
TUNEL Assay: For visualization of apoptotic cells in situ, terminal transferase-mediated dUTP 
nick-end labeling (TUNEL) method was utilized according to the protocol provided by the 
manufacturer (TACS™ TdT Kit, R&D Systems, MN, USA). Counterstaining was performed 
using methyl green solution. Seven different fields (3 cortex, 2 outer medulla, 2 inner medulla) 
from each mouse kidney section were considered for evaluation. TUNEL-positive cells from 
each field were grouped in two nephron segments, namely proximal tubule (glomerulus and 
proximal tubules) and distal nephrons (distal tubule, loops of Henle, and collecting ducts) and  
the average was reported. 
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Results 
 The activities of LMP2 and LMP10 within the immunoproteasome beta-ring were 
assessed using immunohistochemical analysis, which has the advantage of determining the tissue 
distribution of these antigens of interest. Rat kidneys exposed to CS (18 hr) followed by 
transplantation in a new recipient rat (CS/Tx) resulted in a greater activation of both LMP2 and 
LMP10 when compared to sham kidneys (rats with removal of the right kidney, but no CS or Tx) 
and ATx kidneys (rats with removal of the left kidney with Tx, but no CS). Compared to kidneys 
from sham rats, kidneys subjected to CS/Tx showed impaired renal function 24 hr after 
transplantation with an increased number of inflammatory cytokines due to high levels of  
homeostatic stress. Semi-quantitative evaluation of the staining was based on the percentage of 
positive tubules in 10 high power fields (200×) from cortex and medulla (see Figure 4).  
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Figure 4. IHC results with LMP2 antibody 
 As already mentioned, within the immunoproteasome beta-ring there are seven 
proteasome subunits (refer to Figure 1). This research focused on the LMP2 (B1i) subunit. These 
pictures taken with a Nikon Eclipse E800 microscope (Q Capture imaging and Nikons elements 
software) show the localization of immune cells and proteasome at the cellular level. Positive 
brown staining in these tubular cells indicates greater activation of LMP2 during CS/Tx in both 
the cortex and medulla region of the renal tissue. As shown, there is hardly any positive brown 
staining in the Sh and ATx conditions, indicating that CS/Tx causes renal damage and 
dysfunction. Around twenty images were taken for each renal transplant condition and were 
given a score of 1 to 5 (0 - null/negative; 1 - 10% positivity; 2 - 25% positivity; 3 - 50% 
positivity; 4 - 75% positivity; 5 - 100% positivity) to quantify the number of positive cells, and 
then they were averaged. The graph in Figure 4 shows that between about 85% of the tubular 
cells in the CS/Tx condition had a positive brown staining, and only about 10% of the tubular 
cells in the Sh and ATx condition had a positive brown staining. These results show that 
immunoproteasome function was significantly increased when the kidneys were exposed 
 to CS/Tx. 
 This research also focused on the LMP10 (B2i) subunit within the immunoproteasome 
beta-ring. These pictures taken using a Nikon Eclipse E800 microscope (Q Capture imaging and 
Nikons elements software) show the localization of immune cells and proteasome at the cellular 
level. Positive brown staining in these tubular cells indicates greater activation of LMP10 during 
CS/Tx in both the cortex and medulla region of the renal tissue. As you can see, there is hardly 
any positive brown staining in the ATx conditions, indicating that CS/Tx causes renal damage 
28
and disfunction. However, in the Sh images there is also a brown-staining within the tubular 
cells, which was not expected. It was concluded that the LMP10 sham sections were 
compromised; further testing with an increased section number would be necessary to determine 
if sham sections were flawed or if this particular antibody did not work. However, the data in  
Figure 5, with CS/Tx levels reaching almost 60%, still shows that overall immunoproteasome 
function is up-regulated in renal cells exposed to cold storage. 
 The activities of C3, an immune protein that plays a central role within the complement 
system, were assessed using immunohistochemical analysis to quantify the amount of positive 
brown-stating within the cortex and medullar regions of the renal tissue. Immunofluorescent  
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Figure 5. IHC results with LMP10 antibody
analysis was used to measure the levels of C5b-9, the membrane attack complex within the 
complement system, which allows not only for the detection of the antigen in a specific location  
within the renal cells, but also gives a level of expression based on fluorescence. Rat kidneys 
exposed to CS (18 hr) followed by transplantation in a new recipient rat (CS/Tx) resulted in a 
greater activation of both C3 and C5b-9 when compared to sham kidneys (rats with removal of 
the right kidney, but no CS or Tx) and ATx kidneys (rats with removal of the left kidney with Tx, 
but no CS). Compared to kidneys from sham rats, kidneys subjected to CS/Tx showed impaired 
renal function 24 hours after transplantation with an increased number of phagocytic cells, which 
clear foreign and damaged material. Semi-quantitative evaluation of the cortex and medulla C3 
staining was performed based on fluorescent levels detected by the ImageJ software. 
 As mentioned, the complement system, also known as the complement cascade (refer to 
Figure 2), is a group of serum proteins within the immune system that detects and gets rid of 
pathogens within the tissue. C3, specifically, is an immure protein that, when activated,  
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Figure 6. IHC results with C3 antibody
stimulates the rest of the cascade to completion. These pictures taken with a Nikon Eclipse E800 
microscope (Q Capture imaging and Nikons elements software) show the localization of this 
immune protein at the cellular level. Positive brown staining in these tubular cells indicates 
greater activation of C3 during CS/Tx in the cortex region of the renal tissue. As you can see in 
Figure 6, there is hardly any positive brown staining in the Sh and ATx conditions, indicating that 
CS/Tx causes renal damage and dysfunction. The small amount of brown staining that there is in 
the ATx image is not within the nuclear region of the cells but along the outer membrane, 
whereas, in the CS/Tx image the same thing cannot be said; there is a large amount of brown 
staining in the nuclear region of those cells. No semi-quantitative evaluation was done with the 
C3 antibody images because of time constraints during the research process.  
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Figure 7. IFC results with C5b-9 antibody
 At the end of the complement cascade is C5b-9, the membrane attack complex, that when 
activated leads to cell lysis or cell death. These pictures taken with a Nikon Eclipse E800 
microscope (Q Capture imaging and Nikons elements software) show the fluorescent activation 
levels of this immune protein at the cellular level. Brighter fluorescent staining in these tubular 
cells indicates greater activation of C5b-9 during CS/Tx in the cortex and medullar regions of the 
renal tissue. As you can see in Figure 7, the red fluorescent color is much stronger and defined in 
the CS/Tx condition as compared to the Sh. Using the DAPI counterstain, the images showed 
much brighter, almost neon green, nuclei in the CS/Tx condition that cannot be seen in the Sh 
image. The C5b-9 antibody image and the C5b-9 with DAPI image for both conditions were 
overlaid using ImageJ software to produce two contrasting photos. In the CS/Tx overlay image 
you are able to see both the red fluorescence of the tubular cells and the DAPI counterstain of the 
nuclei, whereas, in the Sh overlay image you can only see the DAPI counterstain. The graph in 
Figure 7, with data produced from the ImageJ software, affirms that C5b-9 levels were much 
greater in CS/Tx kidneys than in Sh kidneys. All of this data allows us to conclude that CS/Tx 
exacerbates the function of C5b-9, leading to a greater amount of cell lysis or cell death. 
  
 A terminal transferase-mediated dUTP nick-end labeling (TUNEL) assay was performed 
to further examine the cell death that was seen with both the immunohistochemical analysis of 
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Figure 8. TUNEL assay results
C3 and the immunofluorescent analysis of C5b-9. Rat kidneys exposed to CS (18 hr) followed by 
transplantation in a new recipient rat (CS/Tx) resulted in a larger number of apoptotic cells when 
compared to sham kidneys (rats with removal of the right kidney, but no CS or Tx) and ATx 
kidneys (rats with removal of the left kidney with Tx, but no CS). As you can see in Figure 8, the 
dark purple spots are the apoptotic cells, and there is a much larger amount in the CS/Tx image 
than there is in both the Sh and ATx images. TUNEL-positive cells were quantified by separating 
the images for each condition into four quadrants, counting the number of apoptotic cells in each 
quadrant, and then taking an average of all the images. The graph in Figure 8 validates what is 
seen in the images next to it; there were more than 100 positive nuclei per field in the CS/Tx 
condition, close to 15 positive nuclei per field in the ATx, and nearly zero in the Sh condition. 
This data of apoptotic cells from a TUNAL assay substantiates the data of cell lysis that was 
obtained from the immunohistochemical analysis of C3 and the immunofluorescent analysis of 
C5b-9. All of this data allows us to conclude that CS/Tx not only activates the complement 
cascade, which enhances the ability of phagocytic cells to clear harmful material, but also leads 
to large amounts of apoptosis within renal cells.  
Conclusions 
 The availability of human kidneys for clinical transplantation is limited and the need of 
transplantable, good quality human organs is increasing by the hour. Therefore, it is crucial to 
improve organ preservation quality to maximize procured renal allograft for clinical 
transplantation, and that includes associating prolonged CS with a better long-term outcome. The 
long-term goal of the Parajuli Lab is to improve the transplant outcome by identifying CS-
mediated renal damage and by acquiring targeted therapies during CS. This study contributed to 
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that objective by characterizing immunoproteasome (a proteasome variant) and the complement 
system (a group of serum proteins that participates in eliminating pathogens and debris) 
activation within the kidneys after CS/Tx. Lewis rat kidneys exposed to 18 hours of cold storage 
were used for transplantation (CS/Tx). Kidneys with no CS exposure were transplanted (ATx) 
and used as a transplant control. The sham (Sh) kidneys with right nephrectomy were used as a 
control. Using paraffin embedded kidney sections and immunohistochemistry/
immunofluorescence, the levels and function of immunoproteasome and the complement system 
were evaluated. Our hypothesis was that CS/Tx would exacerbate the function of 
immunoproteasome and the complement system. This research study supported our hypothesis 
by clearly demonstrating that CS/Tx increases immunoproteasome expression and function, and 
CS/Tx increases activation of the complement system. Furthermore, increased 
immunoproteasome and complement activation after CS/Tx correlates with increased renal 
damage and dysfunction. These results highlight the importance of studying how transplant 
conditions, specifically cold storage solution, affect renal tissue, so the preservation of renal 
allograft can be prolonged and the quality of transplant organs can be improved.  
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